Oculis Appoints Katie Kazem as Chief Legal Officer
MWN-AI** Summary
Oculis Holding AG, a global biopharmaceutical company spearheading innovations in neuro-ophthalmology and ophthalmology, has appointed Katie Kazem as its new Chief Legal Officer (CLO). With over 15 years of extensive experience in corporate governance and securities law, Kazem has built a distinguished career as legal counsel for major life sciences firms. Her appointment is particularly timely, as Oculis advances its late-stage product pipeline, including the neuroprotective candidate Privosegtor, which is entering registrational trials under the PIONEER program, and OCS-01, an innovative eye drop treatment for diabetic macular edema (DME) with pivotal results expected in Q2 2026.
Riad Sherif, M.D., CEO of Oculis, expressed enthusiasm about Kazem's appointment, stating it enhances the leadership capabilities required to meet significant clinical and regulatory milestones ahead. Kazem, who has acted as external legal counsel for Oculis since its NASDAQ listing in March 2023, expressed her excitement about joining the company, emphasizing her commitment to advancing Oculis’ promising pipeline.
Prior to her role at Oculis, Ms. Kazem was a capital markets partner at Cooley LLP, where she managed a plethora of transactions for life sciences companies, including IPOs, mergers and acquisitions, and SEC compliance. Her insights into dual-listed biotechnology firms across Europe uniquely position her to navigate Oculis' growth trajectory.
As Oculis gears up for critical developments, Kazem’s legal expertise will be invaluable in steering the company through regulatory landscapes and corporate governance challenges, as it aims to deliver transformative therapies to address significant unmet medical needs in the field. The company’s pipeline also includes Licaminlimab, targeting dry eye disease, marking Oculis as a key player in the biopharmaceutical industry.
MWN-AI** Analysis
The recent appointment of Katie Kazem as Chief Legal Officer at Oculis Holding AG marks a significant strategic move for the company, which specializes in neuro-ophthalmology and ophthalmology. With her rich background in corporate governance and securities law, particularly in the life sciences sector, Kazem is expected to enhance Oculis’ leadership capacity as the company accelerates toward crucial clinical and regulatory milestones.
Investors should regard this appointment positively, given that Kazem has a strong track record in advising biopharmaceutical firms through complex transactions and regulatory compliance. Her prior experience as external legal counsel to Oculis provides her with valuable insights into the company’s strategic framework and potential legal hurdles. With her at the helm of the legal team, Oculis may mitigate risks associated with regulatory challenges as it prepares for significant undertakings such as the forthcoming DIAMOND Phase 3 results for OCS-01, which is poised to become a first-of-its-kind non-invasive treatment for diabetic macular edema.
As Oculis advances its late-stage assets, including the neuroprotective candidate Privosegtor, the company is positioned well to capitalize on upcoming clinical milestones. This momentum can potentially lead to commercialization opportunities that would enhance shareholder value.
Moreover, the market environment for biopharmaceuticals remains conducive, with a growing focus on innovative therapies for complex conditions. Investors should closely monitor Oculis' developments, as the legal and regulatory expertise brought by Kazem could catalyze timely and efficient pathways to market for their differentiated pipeline.
In summary, Oculis presents a compelling investment case amid its aspirations to pioneer in neuro-ophthalmology, especially considering its strong leadership and promising clinical candidates. However, prospective investors should keep a watchful eye on upcoming trial results and regulatory interactions, as these factors could impact stock performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Ms. Kazem brings extensive and global expertise in corporate governance and securities law, drawing on a distinguished track record as external legal counsel to leading life sciences companies
- Chief Legal Officer (CLO) appointment enhances leadership capabilities to advance three highly differentiated late-stage assets toward near-term clinical and regulatory milestones
ZUG, Switzerland, February 17, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced the appointment of Katie Kazem as Chief Legal Officer, leading Oculis’ legal, compliance and corporate governance functions. Ms. Kazem brings extensive expertise in corporate and securities law, with a distinguished track record advising public and private life sciences companies on complex transactions and regulatory matters.
Riad Sherif, M.D., Chief Executive Officer of Oculis, stated “Katie joins Oculis at an exciting moment, with Privosegtor advancing into the PIONEER program with registrational trials for a novel neuroprotective platform and just ahead of the much-anticipated DIAMOND Phase 3 topline results for OCS-01 eye drops in DME, expected in Q2. This significant momentum reinforces our commitment to delivering transformational therapies. I look forward to working alongside Katie as we continue to make rapid progress across our highly differentiated pipeline and prepare for important late-stage clinical, regulatory, and commercial milestones."
Katie Kazem, Chief Legal Officer of Oculis, said “I am honored to be joining Oculis at such an important stage of the company’s journey to become a global leader in neuro-ophthalmology and ophthalmology. Over the past few years, I have had the privilege of serving as external legal counsel to Oculis since its listing on NASDAQ in March 2023, which allowed me to work closely with its exceptional executive team and board of directors, witness the company’s remarkable progress and unwavering business integrity, and gain deeper insight into its highly promising pipeline. I look forward to continuing this collaboration as we advance the company’s late-stage assets toward future clinical milestones and commercialization.”
Ms. Kazem brings to Oculis over 15 years of experience representing life sciences companies on US initial public offerings (IPOs), capital raising, M&A and strategic transactions, SEC compliance, and corporate governance. She joins Oculis from Cooley LLP, a leading international law firm, where she was a capital markets partner. At Cooley, she represented dozens of publicly traded life sciences and technology companies in their IPOs, acquisitions, follow-on offerings, and strategic licensing transactions. She has particular expertise in advising dual-listed biotechnology companies across Europe. Her experience spans both company-side and underwriter-side representations across the life sciences and technology sectors. Ms. Kazem earned her JD, magna cum laude, from George Mason University School of Law, a Master’s degree in Public Policy from George Mason University School of Public Policy, and a BA in Government from the College of William & Mary.
-ENDS-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: Privosegtor, a breakthrough neuroprotective candidate in the PIONEER program which consists of studies intended to support registration plans for treatment in optic neuropathies like optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION), with potentially broad clinical applications in various other neuro-ophthalmic and neurological diseases; OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema (DME); and Licaminlimab, a novel, topical anti-TNF? in Phase 2, which is being developed with a genotype-based approach to drive precision medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
oculis@icrhealthcare.com
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy, including planned interactions with the FDA; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; statements about market opportunity, and the Company’s expected financial position and cash runway, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
FAQ**
How do you envision your role as Chief Legal Officer at Oculis Holding AG OCS influencing the company's strategy during the pivotal late-stage clinical trials currently underway?
In light of your extensive experience, how will you implement best practices in corporate governance at Oculis Holding AG OCS to ensure regulatory compliance and ethical standards?
Given Oculis Holding AG OCS's focus on breakthrough innovations, how do you plan to support the legal aspects of the commercialization strategies for Privosegtor and OCS-01?
How can your background in dual-listed biotech companies across Europe benefit Oculis Holding AG OCS in navigating global regulatory challenges and capital markets?
**MWN-AI FAQ is based on asking OpenAI questions about Oculis Holding AG (NASDAQ: OCS).
NASDAQ: OCS
OCS Trading
0.14% G/L:
$28.04 Last:
237,899 Volume:
$28.33 Open:
